参考文献/References:
[1] Yancy CW, Jessup M, Bozkurt B,et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction[J]. J Am Coll Cardiol,2013,61(4):485-510.
[2] Steg PG, James SK, Atar D, et al.ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].Eur Heart J,2012,33(20):2569-2619.
[3] Amsterdam EA, Wenger NK, Brindis RG,et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Circulation,2014,130(25):2354-2394.
[4] Tang N, Yin S, Sun Z,et al.The relationship between on-clopidogrel platelet reactivity,genotype,and post-percutaneous coronary intervention outcomes in Chinese patients[J].Scand J Clin Lab Invest,2015,75(3):223-229.
[5] Lee CW.Dual antiplatelet therapy for coronary artery disease[J].Circ J,2015,79(2):255-262.
[6] Ramaraj R, Movahed MR, Hashemzadeh M. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome[J]. J Interv Cardiol,2011,24:199-207.
[7] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361:1045-1057.
[8] Montalescot G, Lassen JF, Hamm CW, et al. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery(ATLANTIC)study[J]. Am Heart J,2013,165(4):515-522.
[9] Bonaca MP, Bhatt DL,Cohen M,et al.Long-term use of ticagrelor in patients with prior myocardial infarction[J].N Engl J Med,2015,372(19):1791-1800.
[10] de Servi S, Goedicke J, Schirmer A,et al.An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel[J].Curr Med Res Opin,2014,30(11):2193-2205.
[11] Montalescot G, Bolognese L, Dudek D,et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes[J]. N Engl J Med,2013,369(11):999-1010.
[12] Musumeci G, Limbruno U.The CHAMPION PHOENIX study[J].G Ital Cardiol,2013,14(10):641-646.
[13] Voeltz MD, Manoukian SV.Cangrelor in patients undergoing cardiac surgery: the BRIDGE study[J].Expert Rev Cardiovasc Ther,2013,11(7):811-816.
[14] Haberstock-Debic H, Andre P, Mills S, et al.A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist[J].J Pharmacol Exp Ther,2011,339(1):54-61.
[15] Welsh RC, Rao SV, Zeymer U, et al.A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial[J]. Circ Cardiovasc Interv,2012,5:336-346.
[16] Van't Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty(On-TIME 2): a multicentre, double-blind, randomised controlled trial[J]. Lancet,2008,372:537-546.
[17] Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial[J].JAMA,2012,307:1817-1826.
[18] Giugliano RP, White JA, Bode C,et al.Early versus delayed, provisional eptifibatide in acute coronary syndromes[J].N Engl J Med,2009,360(21):2176-2190.
[19] Bonaca MP, Scirica BM, Braunwald E,et al.New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial[J].J Am Coll Cardiol,2014,64(22):2318-2326.
[20] Raffoul J, Klein AJ.Dual antiplatelet therapy duration after the placement of a drug-eluting stent: what are the data?[J].Curr Treat Options Cardiovasc Med,2015,17(3):367.
[21] Shen Y, Shen WF.Optimizing the duration of dual antiplatelet therapy after implantation of drug-eluting coronary stents[J].Chin Med J(Engl),2015,128(6):711-713.
[22] Zhu HC, Li Y, Guan SY, et al.Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study[J].J Geriatr Cardiol,2015,12(1):23-29.
相似文献/References:
[1]徐娜,综述,袁晋青,等.高龄非血运重建急性冠状动脉综合征患者的抗血小板治疗进展[J].心血管病学进展,2016,(2):108.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.003]
XU Na,YUAN Jinqing.Progress of Antiplatelet Therapy in Senior Patients with Acute
Coronary Syndrome without Revascularization[J].Advances in Cardiovascular Diseases,2016,(5):108.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.003]
[2]徐俊波 黄刚 蔡琳 刘汉雄 张廷杰.老老年患者抗血小板治疗的循证临床实践[J].心血管病学进展,2019,(8):1123.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.013]
XU Junbo,HUANG Gang,CAI Lin,et al.Evidence-based Antiplatelet Treatment in Very Elderly Patients in Clinical Practice[J].Advances in Cardiovascular Diseases,2019,(5):1123.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.013]
[3]朱志伦 田乃亮.急性冠脉综合征患者抗血小板降阶治疗方案研究进展[J].心血管病学进展,2021,(6):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
ZHU Zhilun,TIAN Nailiang.Advances in De-Escalation of Anti-Platelet Therapy in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(5):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
[4]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(5):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
[5]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(5):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[6]徐蓉玮 王亚玲.冠状动脉非阻塞性心肌梗死抗血小板治疗作用[J].心血管病学进展,2022,(10):888.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.006]
XU RongweiWANG Yaling.Role of Antiplatelet Therapy in Myocardial Infarction with Non-obstructive Coronary Arteries[J].Advances in Cardiovascular Diseases,2022,(5):888.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.006]
[7]刘娟 熊诗强 蔡琳.经皮冠状动脉介入治疗术后出血风险评估研究进展[J].心血管病学进展,2023,(4):303.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.004]
LIU Juan,XIONG Shiqiang,CAI Lin.Bleeding Risk Assessment After Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2023,(5):303.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.004]
[8]吕易非 李紫凡 邵褀睿 韩江莉.急性冠脉综合征合并高出血风险患者双联抗血小板治疗研究进展[J].心血管病学进展,2023,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
LV Yifei,LI Zifan,SHAO Qirui,et al.Dual Antiplatelet Therapy for Patients with Acute Coronary Syndrome and High Bleeding Risk[J].Advances in Cardiovascular Diseases,2023,(5):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
[9]努尔古丽·玉苏普 古力尼尕尔·麦麦提吐尔孙 陈清杰 艾尔肯·阿吉.急性冠脉综合征合并糖尿病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2023,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]
Nurgul·Yusup,Gulinigar·Mamattursun,CHEN Qingjie,et al.P2Y12 Receptor Antagonist Therapy in A cute Coronary Syndrome with Diabetes[J].Advances in Cardiovascular Diseases,2023,(5):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]
[10]崔鸿杰 吴英锋.CYP2C19基因多态性指导抗血小板治疗的研究现状[J].心血管病学进展,2023,(11):1019.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.014]
Cui Hongjie,Wu Yingfeng.CYP2C19 gene polymorphism for antiplatelet therapy[J].Advances in Cardiovascular Diseases,2023,(5):1019.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.014]